$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

$nwbo Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000114420415029414 Filed on May 11, 2015

Income Statement

Concept	2015 Q2	2015 Q1	2014 Q1
Revenue	$391.0K	$194.0K	$0.00
YoY Change			-100.0%
Cost Of Revenue			$0.00
YoY Change
Gross Profit			$0.00
YoY Change			-100.0%
Gross Profit Margin
Selling, General & Admin	$9.810M	$3.320M	$3.690M
YoY Change	152.84%	-10.03%	49.39%
% of Gross Profit
Research & Development	$27.80M	$19.63M	$19.99M
YoY Change	29.0%	-1.81%	72.17%
% of Gross Profit
Depreciation & Amortization	$12.00K	$3.000K	$0.00
YoY Change	20.0%
% of Gross Profit
Operating Expenses	$27.80M	$19.63M	$19.99M
YoY Change	29.0%	-1.81%	72.17%
Operating Profit	-$38.85M	-$22.83M	-$23.68M
YoY Change	52.81%	-3.59%	69.84%
Interest Expense	$1.636M	$793.0K	$122.0K
YoY Change	4857.58%	550.0%	-72.89%
% of Operating Profit
Other Income/Expense, Net	-$27.99M	-$23.60M	-$22.36M
YoY Change	6290.64%	5.56%
Pretax Income	-$66.85M	-$46.43M	-$46.04M
YoY Change	158.41%	0.85%	219.94%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$66.85M	-$46.43M	-$46.04M
YoY Change	158.44%	0.85%	219.86%
Net Earnings / Revenue	-17095.91%	-23934.54%
Basic Earnings Per Share	-$0.88	-$0.67
Diluted Earnings Per Share	-$0.88	-$0.67	-$879.0K
COMMON SHARES
Basic Shares Outstanding	76.89M shares	70.31M shares	53.74M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.20M	$3.170M	$12.23M
YoY Change	116.95%	-74.08%	3205.41%
Cash & Equivalents	$19.20M	$3.170M	$12.23M
Short-Term Investments
Other Short-Term Assets	$2.000M	$1.550M	$150.0K
YoY Change	-44.29%	933.33%	275.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$21.20M	$4.715M	$12.38M
YoY Change	70.37%	-61.91%	2919.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$42.00M	$41.39M	$80.00K
YoY Change	54444.16%	51632.5%	-11.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.050M	$55.00K	$60.00K
YoY Change	1809.09%	-8.33%	200.0%
Total Long-Term Assets	$43.05M	$44.70M	$130.0K
YoY Change	32511.36%	34283.08%	18.18%
TOTAL ASSETS
Total Short-Term Assets	$21.20M	$4.715M	$12.38M
Total Long-Term Assets	$43.05M	$44.70M	$130.0K
Total Assets	$64.25M	$49.41M	$12.51M
YoY Change	410.89%	294.99%	2305.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.07M	$9.744M	$6.620M
YoY Change	16.02%	47.19%	-49.31%
Accrued Expenses	$1.188M	$940.0K	$760.0K
YoY Change	81.37%	23.68%	-29.63%
Deferred Revenue
YoY Change
Short-Term Debt	$930.0K	$930.0K	$930.0K
YoY Change	0.0%	0.0%	-30.08%
Long-Term Debt Due	$240.0K	$240.0K	$240.0K
YoY Change	0.0%	0.0%	-68.83%
Total Short-Term Liabilities	$116.5M	$90.97M	$43.57M
YoY Change	174.56%	108.79%	168.29%
LONG-TERM LIABILITIES
Long-Term Debt	$23.72M	$29.00M	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$149.0K	$148.0K
YoY Change
Total Long-Term Liabilities	$23.87M	$29.14M	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$116.5M	$90.97M	$43.57M
Total Long-Term Liabilities	$23.87M	$29.14M	$0.00
Total Liabilities	$140.4M	$120.1M	$43.57M
YoY Change	230.79%	175.68%	148.12%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$557.2M	$496.5M
YoY Change	30.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$76.17M	-$70.70M	-$31.06M
YoY Change
Total Liabilities & Shareholders Equity	$64.25M	$49.41M	$12.51M
YoY Change	410.88%	294.99%	2305.77%

Cashflow Statement

Concept	2015 Q2	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$66.85M	-$46.43M	-$46.04M
YoY Change	158.44%	0.85%	219.86%
Depreciation, Depletion And Amortization	$12.00K	$3.000K	$0.00
YoY Change	20.0%
Cash From Operating Activities	-$27.10M	-$17.58M	-$10.56M
YoY Change	59.98%	66.51%	49.26%
INVESTING ACTIVITIES
Capital Expenditures	-$890.0K	$1.133M	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$890.0K	-$1.133M	$0.00
YoY Change	-73.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$224.0K
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	43.20M	$8.510M	$4.290M
YoY Change	154.42%	98.37%	4147.52%
NET CHANGE
Cash From Operating Activities	-27.10M	-$17.58M	-$10.56M
Cash From Investing Activities	-890.0K	-$1.133M	$0.00
Cash From Financing Activities	43.20M	$8.510M	$4.290M
Net Change In Cash	15.21M	-$10.21M	-$6.269M
YoY Change	-551.34%	62.79%	-10.1%
FREE CASH FLOW
Cash From Operating Activities	-$27.10M	-$17.58M	-$10.56M
Capital Expenditures	-$890.0K	$1.133M	$0.00
Free Cash Flow	-$26.21M	-$18.72M	-$10.56M
YoY Change		77.24%	49.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55000	USD
CY2015Q1	dei	Trading Symbol TradingSymbol	NWBO
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	76889028	shares
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	NORTHWEST BIOTHERAPEUTICS INC
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001072379
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	238000	USD
CY2015Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	238000	USD
CY2015Q1	us-gaap	Notes Payable Current NotesPayableCurrent	934000	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	934000	USD
CY2014Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	44742000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	68880000	USD
CY2015Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	17500000	USD
CY2014Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	17500000	USD
CY2015Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	29144000	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	24588000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	93468000	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	70000	USD
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	496443000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	-70699000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49413000	USD
CY2015Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	67081000	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	69000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	485615000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-35027000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58441000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	90968000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	120112000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55000	USD
CY2015Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	44698000	USD
CY2014Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	43799000	USD
CY2015Q1	us-gaap	Assets Assets	49413000	USD
CY2014Q4	us-gaap	Assets Assets	58441000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	940000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1211000	USD
CY2015Q1	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	566954000	USD
CY2014Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	520521000	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-258000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-190000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3170000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13390000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	666000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	387000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	4715000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	14642000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41386000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39999000	USD
CY2015Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	1939000	USD
CY2014Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	1985000	USD
CY2015Q1	nwbo	Cash Payments CashPayments	8200000	USD
CY2014Q1	nwbo	Cash Payments For Services CashPaymentsForServices	1000000	USD
CY2015Q1	nwbo	Cash Payments For Services CashPaymentsForServices	5800000	USD
CY2015Q1	us-gaap	Accrued Environmental Loss Contingencies Noncurrent AccruedEnvironmentalLossContingenciesNoncurrent	6200000	USD
CY2015Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">  </font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, valuing environmental liabilities, estimating the fair value of equity instruments recorded as derivative liabilities, and estimating the useful lives of depreciable assets and whether impairment charges may apply.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	20000000	USD
CY2015Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	19700000	USD
CY2015Q1	nwbo	Share Based Compensation Aggregate Non Cash Charges For Non Cash Interest Associated With Accretion Of Our Convertible Notes Discount Net ShareBasedCompensationAggregateNonCashChargesForNonCashInterestAssociatedWithAccretionOfOurConvertibleNotesDiscountNet	29400000	USD
CY2015Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	3200000	USD
CY2015Q1	nwbo	Current Assets Less Payables CurrentAssetsLessPayables	86300000	USD
CY2015Q1	nwbo	Convertible Notes Payable Related Parties ConvertibleNotesPayableRelatedParties	5800000	USD
CY2015Q1	nwbo	Working Capital Deficit WorkingCapitalDeficit	46400000	USD
CY2014Q3	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	6200000	USD
CY2014Q1	nwbo	Cash Payments CashPayments	5300000	USD
CY2015Q1	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual High Estimate SiteContingencyLossExposureInExcessOfAccrualHighEstimate	4500000	USD
CY2015Q1	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual Low Estimate SiteContingencyLossExposureInExcessOfAccrualLowEstimate	32000000	USD
CY2014Q1	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2015Q1	us-gaap	Revenue From Grants RevenueFromGrants	194000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	194000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19986000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19703000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-23682000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22831000	USD
CY2014Q1	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	5251000	USD
CY2015Q1	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3693000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3319000	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3000	USD
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3000	USD
CY2014Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	23682000	USD
CY2015Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	23025000	USD
CY2015Q1	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual Best Estimate SiteContingencyLossExposureInExcessOfAccrualBestEstimate	6200000	USD
CY2015Q1	nwbo	Accrued Expenses Related Party AccruedExpensesRelatedParty	9000	USD
CY2014Q4	nwbo	Accrued Expenses Related Party AccruedExpensesRelatedParty	8000	USD
CY2015Q1	nwbo	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	50000	USD
CY2014Q4	nwbo	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	50000	USD
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70310724	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68957469	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70310724	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68957469	shares
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6400000	USD
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3100000	USD
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.37
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	41549000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	40159000	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	163000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	160000	USD
CY2015Q1	us-gaap	Depreciation Depreciation	3000	USD
CY2014Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-16984000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	122000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	793000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-46041000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-46433000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
CY2015Q1	us-gaap	Notes Payable NotesPayable	1172000	USD
CY2014Q4	us-gaap	Notes Payable NotesPayable	1172000	USD
CY2014Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	17500000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52377000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69406000	shares
CY2015Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	50000	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	50000	USD
CY2014Q1	nwbo	Stock And Warrants Issued For Services And Other Expenses StockAndWarrantsIssuedForServicesAndOtherExpenses	1567000	USD
CY2015Q1	nwbo	Stock And Warrants Issued For Services And Other Expenses StockAndWarrantsIssuedForServicesAndOtherExpenses	0	USD
CY2014Q1	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	0	USD
CY2015Q1	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	279000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	277000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-378000	USD
CY2014Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	3363000	USD
CY2015Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	103000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10559000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17582000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1133000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1133000	USD
CY2014Q3	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.0730	pure
CY2014Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	16200000	USD
CY2015Q1	nwbo	Percentage Of Initial Purchase Price PercentageOfInitialPurchasePrice	0.3	pure
CY2015Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	2600000	USD
CY2015Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.12	pure
CY2015Q1	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	151.4142	pure
CY2015Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24272000	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32678000	shares
CY2015Q1	nwbo	One Time Charges Of Service Agreement OneTimeChargesOfServiceAgreement	8200000	USD
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	29385000	shares
CY2015Q1	nwbo	Number Of Warrants Warrants Exercised On Cashless Basis NumberOfWarrantsWarrantsExercisedOnCashlessBasis	117000	shares
CY2015Q1	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	888000	shares
CY2015Q1	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	128000	shares
CY2015Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	28330000	shares
CY2014Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	4.72
CY2015Q1	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	4.11
CY2015Q1	nwbo	Weighted Average Exercise Pricewarrants Exercised On Cashless Basis WeightedAverageExercisePricewarrantsExercisedOnCashlessBasis	3.35
CY2015Q1	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	9.42
CY2015Q1	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	4.72
CY2015Q1	nwbo	Fair Value Of Warrants At Issuance Date FairValueOfWarrantsAtIssuanceDate	500000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	888187	shares
	nwbo	Warrants Issued During Period WarrantsIssuedDuringPeriod	14323003	shares
	nwbo	Warrants Issued Weighted Average Exercise Price Per Warrant WarrantsIssuedWeightedAverageExercisePricePerWarrant	3.3
	nwbo	Warrants Issued Weighted Average Remaining Contractual Term WarrantsIssuedWeightedAverageRemainingContractualTerm	P4Y4M24D
CY2015Q1	us-gaap	Stock Issued During Period Value Issued For Noncash Considerations StockIssuedDuringPeriodValueIssuedForNoncashConsiderations	520000	USD
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3651000	USD
CY2015Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	6359000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	234000	USD
CY2014Q1	nwbo	Accrued Interest Converted To Common Stock AccruedInterestConvertedToCommonStock	76000	USD
CY2015Q1	nwbo	Accrued Interest Converted To Common Stock AccruedInterestConvertedToCommonStock	0	USD
CY2014Q1	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	7961000	USD
CY2015Q1	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	6359000	USD
CY2014Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1400000	USD
CY2015Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2014Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	25000	USD
CY2015Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2014Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2692000	USD
CY2015Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3651000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	224000	USD
CY2014Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4290000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8510000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6269000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10220000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18499000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12230000	USD
CY2014Q1	nwbo	Reclass Of Redeemable Security To Equity ReclassOfRedeemableSecurityToEquity	8913000	USD
CY2015Q1	nwbo	Reclass Of Redeemable Security To Equity ReclassOfRedeemableSecurityToEquity	0	USD
CY2015Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	11496000	USD
CY2014Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	6990000	USD
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	148000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	98000	USD
CY2014Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-2000	USD
CY2015Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	349000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	68000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-46041000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-46501000	USD
CY2015Q1	nwbo	Fair Value Of Common Stock Issued For Redemption Of Redeemable Securities FairValueOfCommonStockIssuedForRedemptionOfRedeemableSecurities	300000	USD
CY2015Q1	nwbo	Stock Issued During Period Value Redeemable Securities Settlement StockIssuedDuringPeriodValueRedeemableSecuritiesSettlement	299000	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Mortgage Loans Held For Sale ProceedsFromSaleOfMortgageLoansHeldForSale	0	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Mortgage Loans Held For Sale ProceedsFromSaleOfMortgageLoansHeldForSale	4997000	USD
CY2015Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	20000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	80068	shares
CY2015Q1	nwbo	Number Of Warrants Adjustment Related To Prior Issued Warrants NumberOfWarrantsAdjustmentRelatedToPriorIssuedWarrants	16000	shares
CY2015Q1	nwbo	Weighted Average Exercise Price Adjustment Related To Prior Issued Warrants WeightedAverageExercisePriceAdjustmentRelatedToPriorIssuedWarrants	5.73
CY2015Q1	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	879000	USD
CY2014Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	865000	USD
CY2015Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	1318000	USD
CY2014Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	1760000	USD
CY2015Q1	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	6200000	USD
CY2014Q4	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	6200000	USD
CY2015Q1	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	300000	USD
CY2014Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2015Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	138000	USD
CY2014Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2015Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	349000	USD
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2015Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-15000	USD
CY2015Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	67100000	USD
CY2015Q1	nwbo	Noncash Derivative Liability NoncashDerivativeLiability	86100000	USD
CY2015Q1	nwbo	Number Of Warrants Adjusted Due To Price Reset NumberOfWarrantsAdjustedDueToPriceReset	62000	shares
CY2015Q1	nwbo	Weighted Average Price Of Warrant Adjustment Due To Price Reset WeightedAveragePriceOfWarrantAdjustmentDueToPriceReset	3.35
CY2014Q1	nwbo	Warrant Exercise On Warrant Liability WarrantExerciseOnWarrantLiability	0	USD
CY2015Q1	nwbo	Warrant Exercise On Warrant Liability WarrantExerciseOnWarrantLiability	520000	USD
CY2014Q1	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	USD
CY2015Q1	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	257000	USD
CY2014Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2015Q1	us-gaap	Interest Paid Net InterestPaidNet	428000	USD
CY2014Q1	nwbo	Redeemable Security Settlement RedeemableSecuritySettlement	0	USD
CY2015Q1	nwbo	Redeemable Security Settlement RedeemableSecuritySettlement	299000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9744000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9826000	USD
CY2015Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	5831000	USD
CY2014Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	5729000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	0	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	735000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	46500000	USD
CY2015Q1	nwbo	Stock Issued During Period Shares Cashless Exercise Of Warrants StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants	385000	shares
CY2015Q1	nwbo	Fair Value Of Common Stock FairValueOfCommonStock	6.07	USD
CY2014Q1	nwbo	Accrued Exit Fee Incurred From Mortgage Loan AccruedExitFeeIncurredFromMortgageLoan	0	USD
CY2015Q1	nwbo	Accrued Exit Fee Incurred From Mortgage Loan AccruedExitFeeIncurredFromMortgageLoan	50000	USD

Files In Submission

Name	View Source	Status
0001144204-15-029414-index-headers.html	Edgar Link	pending
0001144204-15-029414-index.html	Edgar Link	pending
0001144204-15-029414.txt	Edgar Link	pending
0001144204-15-029414-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
nwbo-20150331.xml	Edgar Link	completed
nwbo-20150331.xsd	Edgar Link	pending
nwbo-20150331_cal.xml	Edgar Link	unprocessable
nwbo-20150331_def.xml	Edgar Link	unprocessable
nwbo-20150331_lab.xml	Edgar Link	unprocessable
nwbo-20150331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v408078_10q.htm	Edgar Link	pending
v408078_ex31-1.htm	Edgar Link	pending
v408078_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2015 Q2 Form 10-Q Financial Statement

#000114420415029414 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2015 Q2 Form 10-Q Financial Statement

#000114420415029414 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo